Abstract：Parkinson’s disease(PD) is a common disease of movement disorder in the elderly. It is chronic and progressive. Early clinical manifestations are not typical and it is easy to be misdiagnosed. But L-dopa is effective and early treatment can significantly improve the prognosis and living quality of the patients. So early diagnosis of the disease is very important. PET/CT has a high clinical value in the diagnosis of PD, especially in early diagnosis.
崔丽莉，程 刚. PET/CT对帕金森病早期诊断价值的研究[J]. 中国临床医学影像杂志, 2018, 29(6): 435-438.
CUI Li-li, CHENG Gang. The value of PET/CT in early diagnosis of Parkinson’s disease. JOURNAL OF CHINA MEDICAL IMAGING, 2018, 29(6): 435-438.
1]Jankovic J. Parkinson’s disease clinical features and diagnosis[J]. J Neurol Neurosurg Psychiatry, 2008, 79(4): 368-376.
[2]Perlmutter JS, Norris SA. Neuroimaging biomarkers for Parkinson disease: Facts and fantasy[J]. Ann Neurol, 2014, 76(6): 769-783.
[3]Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study[J]. Neurology, 2014, 83(5): 406-412.
[4]Wang J, Hoekstra JG, Zuo C, et al. Biomarkers of Parkinson’s disease: current status and future perspectives[J]. Drug Discov Today, 2013, 18(3-4): 155-162.
[5]Berg D, Lang AE, Postuma RB, et al. Changing the research criteria for the diagnosis of Parkinson’s disease: obstacles and opportunities[J]. Lancet Neurol, 2013, 12(5): 514-524.
[6]Tripathi M, Tang CC, Feigin A, et al. Automated differential diagnosis of early Parkinsonism using metabolic brain networks: A validation study[J]. J Nucl Med, 2016, 57(1): 60-66.
[7]Tripathi M, Dhawan V, Peng S, et al. Differential diagnosis of Parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography[J]. Neuroradiology, 2013, 55(4): 483-492.
[8]郭舜源，张锦华，陈波，等. 帕金森病患者脑部葡萄糖代谢特征分析[J]． 中国现代医生，2016，54（19）：1-4.
[9]Wichmann T, DeLong MR. Pathophysiology of Parkinson’s disease: the MPTP primate model of the human disorder[J]. Ann N Y Acad Sci, 2003, 991(1): 199-213.
[10]蔡增林，吴方萍，周芯羽，等. 早期帕金森病患者的临床与18F-FDG PET影像学特征研究[J]. 中国现代医药杂志，2010，12（2）：61-63.
[11]Garraux G, Phillips C, Schrouff J, et al. Multiclass classification of FDG PET scans for the distinction between Parkinson’s disease and atypical Parkinsonian syndromes[J]． Neuroimage Clin, 2013, 2(1): 883－893．
[12]段中响，欧阳巧洪，张瑾，等. FDG PET扫描多类分类以区别帕金森症和不典型帕金森综合征[J]. 临床和实验医学杂志，2015，14（2）：2000-2003.
[13]Tripathi M, Tang CC, Feigin A, et al. Automated differential diagnosis of early Parkinsonism using metabolic brainnetworks: A validation study[J]. J Nucl Med, 2016, 57(1): 60-66.
[14]Nurmi E, Ruottinen H, Kaasinen V, et al. Progression in Parkinson’s disease: a positron emission tomography study with a dopamine transporter ligand 18F-CFT[J]. Ann Neurol, 2000, 47(6): 804-808.
[15]Ishibashi K, Oda K, Ishiwata K, et al. Comparison of dopamine transporter decline in a patient with Pakinson’s disease and normal aging effect[J]. J Neurol Sci, 2014, 399(1): 207-209.
[16]Liu SY, Wu JJ, Zhao J, et al. Onset-related subtypes of Parkinson’s disease differ in the patterns of striatal dopaminergic dysfunction: A positron emission tomography study[J]. Parkinsonism Relat Disord, 2015, 21(12): 1148-1453.
[17]冼文彪，史新冲，张祥松，等. [11C]CFT脑多巴胺转运体PET显像对帕金森病诊断和严重程度评估的应用[J]. 中国神经精神疾病杂志，2014，40（8）：474-478.
[18]Lee C, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease[J]. Ann Neurol, 2000, 47(6): 493-503.
[19]Ouchi Y, Kanno T, Okada H, et al. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson’s disease: a double-tracer positron emission tomography study[J]. Ann Neurol, 1999, 46(5): 723-731.
[20]赵振凡，陶俊，许志强，等. １１Ｃ-ＣＦＴ脑多巴胺转运体ＰＥＴ显像对帕金森病进展及严重程度的评价[J]. 西部医学，2017，29（6）：782-790.
[21]焦方阳，武猛，王坚，等. 帕金森病不同亚型患者的多巴胺转运体正电子发射断层显像研究[J]. 中国临床神经科学，2015，23（3）：262-267.
[22]许靖，张奇洲，秦永德，等. １１Ｃ-ＣＦＴ脑多巴胺转运体ＰＥＴ显像在不同类型帕金森病患者病情评估中的应用价值[J]. 新疆医科大学学报，2017，40（6）：738-742.
[23]杨晖，沈智辉，徐白萱. 11C-CFT PET/CT显像鉴别多系统萎缩与帕金森病的价值[J]. 中国医学影像学杂志，2017，25（5）：349-353.
[24]Ponsen MM, Stoffers D, Wolters ECh, et al. Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson’s disease[J]. J Neurol Neurosurg Psychiatry, 2010, 81(4): 396-399.
[25]Iranzo A, Lomena F, Stockner H, et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study[J]. Lancet Neurol, 2010, 9(11): 1070-1077.
[26]Adams JR, van Netten H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson’s disease and evidence for presymptomatic compensation[J]. Brain, 2005, 128(12): 2777-2785.
[27]Tatsch K. Positron emission tomography in diagnosis of Parkinson’s disease[J]. Neurodegener Dis, 2010, 7(5): 330-340.
[28]Pavese N, Rivero Bosch M, Lewis SJ, et al. Progression of monoaminergic dysfunction in Parkinson’s disease: a longitudinal 18F-dopa PET study[J]. Neuroimage, 2011, 56(3): 1463-1468.
[29]Auer DP. In vivo imaging markers of neurodegeneration of the substantianigra[J]． Exp Geronto, 2009, 44(1/2): 4-9.
[30]Tatsch K. Positron emission tomography in diagnosis and differential diagnosis of Parkinson’s disease[J]. Neurodegener Dis, 2010, 7(5): 330-340.
[31]Tang CC, Poston KL, Dhawan V, et al. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson’s disease[J]. J Neurosci, 2010, 30(3): 1049-1056.
[32]Wu P, Yu H, Peng S, et al. Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder[J]. Brain, 2014, 137(12): 3122-3128.
[33]Marshall VL, Patterson J, Hadley DM, et al. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging[J]. Nucl Med Commun, 2006, 27(12): 933-937.
[34]房学梅. Micro PET/CT脑显像评价左旋多巴、姜黄素治疗鼠帕金森病的疗效及对比研究[D]. 石家庄：河北医科大学，2013：1-30.
